Anticancer Activity of Ruthenium(III) Complexes in Colon Cancer Cells
Author Information
Author(s): F. Kratz, B. K. Keppler, M. Hartmann, L. Messori, M. R. Berger
Primary Institution: Tumour Biology Center, Clinical Research, Freiburg, Germany
Hypothesis
The cellular uptake of ruthenium(III) complexes is mediated by apotransferrin or transferrin.
Conclusion
Transferrin-bound forms of the ruthenium complexes show higher antiproliferative activity than the free complex.
Supporting Evidence
- Both ruthenium(III) complexes exhibit high anticancer activity in a colorectal carcinoma model in rats.
- Transferrin-bound forms of the complexes show higher antiproliferative activity than the free complex.
- The apotransferrin-bound form of one complex is not as active as the free complex, while the other shows strong activity.
Takeaway
Researchers tested two special metal compounds to see if they could help fight colon cancer, and found that when these compounds are attached to a protein called transferrin, they work even better.
Methodology
The antiproliferative efficacy was compared using the microculture tetrazolium test (MTT) on the human colon cancer cell line SW707.
Limitations
The study does not demonstrate the release of the complexes inside the cells.
Participant Demographics
Human colon cancer cell line SW707 derived from patients with colorectal cancer.
Want to read the original?
Access the complete publication on the publisher's website